Vyome Holdings, Inc.(HIND)

Biotechnology · Cambridge, MA

$1.90-0.03 (-1.55%)

Delayed quote: Oct 6, 2026, 11:22 AM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T15:27:15.302Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:27:15.302Z.

Quote observation: 2026-10-06T15:22:50.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 13,335,909
Total debt · period ending 2026-06-30: 17,310
Cash · period ending 2026-06-30: 7,887,510
TTM operating EBITDA · period ending 2026-06-30: -4,205,648

FMP input reference: 8dac276dab9b72f767ef95dff0a018bdb1655164ea652fec6d95688d7a2c4747

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

HIND EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

HIND Competitors' EV/EBITDA Ratio

HIND

Vyome Holdings, Inc.

Current

Market Cap

$13.34M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PASG

Passage Bio, Inc.

vs HIND

Market Cap

$13.78M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INAB

IN8bio, Inc.

vs HIND

Market Cap

$13.71M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTXR

Citius Pharmaceuticals, Inc.

vs HIND

Market Cap

$14.02M

EV/EBITDA Ratio

N/A

TTM Avg

116.01x

3Y Avg

116.01x

5Y Avg

116.01x

PLSM

Pulsenmore Ltd. Ordinary Shares

vs HIND

Market Cap

$14.24M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OBX

Obsidian Therapeutics Inc.

vs HIND

Market Cap

$14.44M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OPTH

Optimi Health Corp.

vs HIND

Market Cap

$12.95M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTSO

Cytosorbents Corporation

vs HIND

Market Cap

$12.73M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLRB

Cellectar Biosciences, Inc.

vs HIND

Market Cap

$12.94M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KPTI

Karyopharm Therapeutics Inc.

vs HIND

Market Cap

$15.03M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Vyome Holdings, Inc. (HIND)	$13.34M	N/A	N/A	N/A	N/A
Passage Bio, Inc. (PASG)vs ›	$13.78M	N/A	N/A	N/A	N/A
IN8bio, Inc. (INAB)vs ›	$13.71M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$14.02M	N/A	116.01x	116.01x	116.01x
Pulsenmore Ltd. Ordinary Shares (PLSM)vs ›	$14.24M	N/A	N/A	N/A	N/A
Obsidian Therapeutics Inc. (OBX)vs ›	$14.44M	N/A	N/A	N/A	N/A
Optimi Health Corp. (OPTH)vs ›	$12.95M	N/A	N/A	N/A	N/A
Cytosorbents Corporation (CTSO)vs ›	$12.73M	N/A	N/A	N/A	N/A
Cellectar Biosciences, Inc. (CLRB)vs ›	$12.94M	N/A	N/A	N/A	N/A
Karyopharm Therapeutics Inc. (KPTI)vs ›	$15.03M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics